Premium
Risk‐adjusted prognostic models for Hodgkin's disease (HD) and grade II non‐Hodgkin's lymphoma (NHL II): validation on 6728 British National Lymphoma Investigation patients
Author(s) -
Low Su E.,
Horsman Janet M.,
Walters Stephen J.,
Hancock Helen,
Smith Paul,
Linch David,
Hancock Barry W.
Publication year - 2003
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1046/j.1365-2141.2003.04061.x
Subject(s) - lymphoma , medicine , erythrocyte sedimentation rate , multivariate analysis , non hodgkin's lymphoma , disease , stage (stratigraphy) , oncology , lactate dehydrogenase , international prognostic index , hodgkin lymphoma , multivariate statistics , gastroenterology , diffuse large b cell lymphoma , biology , statistics , paleontology , biochemistry , enzyme , mathematics
Summary. Using significant factors from multivariate analyses, based on 20 putative markers from a consecutive series of 1198 Sheffield Lymphoma Group patients, risk‐adjusted prognostic models had been previously derived for Hodgkin's disease (HD) (using age, albumin and lymphocyte count) and non‐Hodgkin's lymphoma (NHL) grade II (based on albumin, age, erythrocyte sedimentation rate, lactate dehydrogenase and stage). Data from 6728 patients on the British National Lymphoma Investigation database were used for validation: thus the models were applied to 4411 patients with HD and 2317 patients with NHL grade II. Survival curves derived from these validation groups confirmed our risk models.